Discovered by Napoleone Ferrara in 1989, it took 15 years from the discovery of the target to the clinical approval of the first VEGF blocking drug, the neutralizing antibody Bevacizumab. Bevacizumab and several other VEGF blocking drugs, VEGF receptor neutralizing and blocking drugs have been widely used in the field of oncology. Anti-angiogenic tumor therapy has therefore become part of the standard treatment of Gastrointestinal Cancers, improving the therapeutic effect tumors treatment. But the full potential of anti-angiogenic therapy has not been fully exploited, neither are some of the key questions in the field of tumor angiogenesis research that have not been answered.
The indications for anti-angiogenic targeted agents in Gastrointestinal Cancers are currently increasing. There is also an increasing number of clinical trials exploring potentially suitable applications for anti-angiogenic targeted agents, such as the combination of anti-angiogenic therapy with other treatments, which offers the possibility of survival benefits for patients with Gastrointestinal Cancers. To date, we can find encouragement in the fact that patients with Gastrointestinal Cancers are now living longer. Since angiogenesis is an essential process for tumor growth, identifying of pro-angiogenic molecules and blocking their pathway represent potential anti-cancer therapeutic approaches. Although preclinical studies on anti-angiogenic therapies have shown promising anti-cancer effects, they still lack of practical application on patients and do not thoroughly eradicate tumors. The development of new anti-angiogenic strategies for effective treatment of Gastrointestinal Cancers is of great significance, for the purpose of overcoming side effects and drug resistance by targeting the multiple angiogenic mechanisms associated with GI cancer.
The mechanism of action of anti-angiogenic tumor therapy is still unclear. No accurate markers or methods have been developed to predict and evaluate the response to anti-angiogenic treatments. What is also unclear is that the mechanism of how tumor microenvironment affects anti-angiogenic process. There are problems with the rational combination of anti-angiogenic drugs. The adverse reactions and resistance mechanisms of anti-angiogenic drugs also need to be further elucidated.
This research topic aims at shedding light on the latest developments, research hotspots, and potential problems in the field of tumor anti-angiogenesis treatments. We welcome the submissions of Review, Mini-Review and Original Research articles covering, but not limited to, the following topics:
• Current and novel strategies of anti-angiogenics therapy in gastrointestinal cancers
• Mechanisms of anti-angiogenic therapy and resistance in gastrointestinal cancers
• Mechanisms of synergy in combinations of anti-angiogenics and other therapies in gastrointestinal cancers
• Anti-tumor angiogenesis biomarkers, response evaluation and adverse reactions in gastrointestinal cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Discovered by Napoleone Ferrara in 1989, it took 15 years from the discovery of the target to the clinical approval of the first VEGF blocking drug, the neutralizing antibody Bevacizumab. Bevacizumab and several other VEGF blocking drugs, VEGF receptor neutralizing and blocking drugs have been widely used in the field of oncology. Anti-angiogenic tumor therapy has therefore become part of the standard treatment of Gastrointestinal Cancers, improving the therapeutic effect tumors treatment. But the full potential of anti-angiogenic therapy has not been fully exploited, neither are some of the key questions in the field of tumor angiogenesis research that have not been answered.
The indications for anti-angiogenic targeted agents in Gastrointestinal Cancers are currently increasing. There is also an increasing number of clinical trials exploring potentially suitable applications for anti-angiogenic targeted agents, such as the combination of anti-angiogenic therapy with other treatments, which offers the possibility of survival benefits for patients with Gastrointestinal Cancers. To date, we can find encouragement in the fact that patients with Gastrointestinal Cancers are now living longer. Since angiogenesis is an essential process for tumor growth, identifying of pro-angiogenic molecules and blocking their pathway represent potential anti-cancer therapeutic approaches. Although preclinical studies on anti-angiogenic therapies have shown promising anti-cancer effects, they still lack of practical application on patients and do not thoroughly eradicate tumors. The development of new anti-angiogenic strategies for effective treatment of Gastrointestinal Cancers is of great significance, for the purpose of overcoming side effects and drug resistance by targeting the multiple angiogenic mechanisms associated with GI cancer.
The mechanism of action of anti-angiogenic tumor therapy is still unclear. No accurate markers or methods have been developed to predict and evaluate the response to anti-angiogenic treatments. What is also unclear is that the mechanism of how tumor microenvironment affects anti-angiogenic process. There are problems with the rational combination of anti-angiogenic drugs. The adverse reactions and resistance mechanisms of anti-angiogenic drugs also need to be further elucidated.
This research topic aims at shedding light on the latest developments, research hotspots, and potential problems in the field of tumor anti-angiogenesis treatments. We welcome the submissions of Review, Mini-Review and Original Research articles covering, but not limited to, the following topics:
• Current and novel strategies of anti-angiogenics therapy in gastrointestinal cancers
• Mechanisms of anti-angiogenic therapy and resistance in gastrointestinal cancers
• Mechanisms of synergy in combinations of anti-angiogenics and other therapies in gastrointestinal cancers
• Anti-tumor angiogenesis biomarkers, response evaluation and adverse reactions in gastrointestinal cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
